4892 — Cyfuse Biomedical KK Cashflow Statement
0.000.00%
Last trade - 00:00- ¥8bn
- ¥6bn
- ¥54m
Annual cashflow statement for Cyfuse Biomedical KK, fiscal year end - December 31st, JPY millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | Yuho | Yuho | Yuho |
| Standards: | JAS | JAS | JAS | JAS | JAS |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -327 | 145 | -472 | -586 | -870 |
| Depreciation | |||||
| Non-Cash Items | -47.2 | -81 | 45.5 | -119 | 40.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 47.8 | 79.1 | -31.4 | 105 | 32.9 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Taxes Payable | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -294 | 162 | -404 | -562 | -761 |
| Capital Expenditures | -0.264 | — | -228 | -19.5 | -8.55 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | -50.6 | -202 | — | -0.091 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.264 | -50.6 | -431 | -19.5 | -8.64 |
| Financing Cash Flow Items | -0.001 | -0.001 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 489 | 229 | 2,659 | 18.2 | -52 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 195 | 340 | 1,824 | -564 | -821 |